Market Snapshot

S&P Futures
4,160.25
Dow Futures
34,003.00
NASDAQ Futures
13,899.00

You don’t want to be left out of the Sensus Healthcare Inc. (SRTS) story

Related Topics

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on whatsapp
WhatsApp

Sensus Healthcare, Inc. (NASDAQ: SRTS), the stock is surging up 16.76% to $4.43.During the last trading session, a price range of $3.82 to $4.19 was noted. At the present time, the company has a market capitalization of 64.10M dollars.

Healthcare company Sensus Healthcare, Inc. provides treatments with a clinical utility that is extremely effective, minimally invasive, and cost-effective, in both oncological and non-oncological conditions.

Recent Development

February 26, 2021, For the three months and calendar year 2020, Sensus Healthcare, Inc. (Nasdaq: SRTS), reported financial results.

During the fourth quarter of 2020 and past weeks, the following highlights were reported:

The quarter saw 18 systems shipped, with 12 sales in the United States and three sales in China.

Holy Name Medical Center in Teaneck, New Jersey has received a system to deliver superficial radiation therapy (SRT) to patients with pneumonia from COVID-19.

CMS has increased its reimbursement for the primary SRT codes to the tune of significant amounts as well as meaningful hikes in Evaluation & Management (E/M) codes.

A retrospective study in the Journal of Clinical and Aesthetic Dermatology reported a 10% recurrence rate following keloidectomy with SRT, compared to an 80% recurrence rate following keloidectomy alone.

The COVID-19 pandemic was addressed by frequent direct outreach and a series of online programs that highlighted the benefits of SRT for treating non-melanoma skin cancer.

Sensus Laser Aesthetic Services, the company’s mobile aesthetic laser business, launched new FDA-cleared aesthetic lasers.

The Sentinel IT Solutions package continues to generate recurring revenue, now included in just-launched aesthetic lasers and the SRT-100 Vision systems.

During the third quarter of 2020, revenues increased from $1.6 million to $5.1 million.

Earnings from continuing operations were $1 million, or $0.06 per diluted share, unchanged from the prior year.

During both the fourth quarters of 2020 and 2019, Adjusted EBITDA amounted to $1.3 million.

Notably,

According to a report from Global Market Insights, the global biotechnology market is expected to surpass US$729 billion by 2025. The growth is mainly influenced by a rise in chronic diseases and the associated healthcare costs. Also contributing to the revenue size are innovative products within the biotechnology sector. This describes growing human organs and plants in labs as well as meat.

Sign up for our FREE Newsletter and get:
Sign up for our FREE Newsletter and get:

SOCIAL LINKS

Latest Posts